During a panel discussion, Darren Taichman, MD, PhD, executive deputy editor of the Annals of Internal Medicine and adjunct associate professor of medicine, Perelman School of Medicine, University of Pennsylvania, presented updates to pulmonary hypertension treatment guidelines, and Daniel Oulette, MD, FCCP, leader of the American College of Chest Physicians guideline oversight committee, discussed the move toward evidence-based guidelines that allow for continuous updates.
According to experts at the 2014 American College of Chest Physicians (ACCP) meeting, evidence-based guidelines are increasingly becoming “living” documents that are continuously updated. Darren Taichman, MD, PhD, executive deputy editor of the Annals of Internal Medicine and adjunct associate professor of medicine, Perelman School of Medicine, University of Pennsylvania, presented updates to the ACCP guideline for diagnosis and treatment of pulmonary hypertension (PH) during a panel discussion.
PH is a disease in which it is critically important to ensure that an accurate diagnosis is established, noted Dr Taichman. Appropriate diagnosis ultimately informs the appropriate therapy. Treatments for one type of PH, such as pulmonary arterial hypertension, may not work for another type of PH, such as chronic hypoxemic lung disease.
Functional classification of PH severity is somewhat subjective, and has some limitations, but in general is clinically useful. This classification, which is known as the World Health Organization Functional Classification (FC), is separated into 4 categories:
In general, treatment PH must begin with vasoreactivity testing. Patients who experience lung vasodilation in response to nitrous oxide inhalation should be considered as candidates for calcium channel blocker therapy. However, in an important caveat, Dr Teichmann stated, “Empirical therapy without vasoreactivity testing is dangerous and potentially even fatal in some patients.”
Several classes of medications are available for treatment of PH. These include endothelin receptor antagonists, soluble guanylate cyclase stimulators, and phosphodiesterase-5 inhibitors. Intranveous agents are also available.
Some fundamentals of treatment, as outlined by Dr Taichmann, include the following:
Also important are influenza vaccinations, and pneumococcal vaccinations in patients with PH. Pregnancy and nonessential surgery should be avoided, and supplemental oxygen may be necessary during air travel.
The new treatment guideline in PH is subject to some limitations. For example, supportive therapy with diuretics, digoxin, oxygen, and anticoagulants is not covered by the guideline. Dr Taichmann recommended referring to the 2007 guidelines for information on use of these supplemental treatments.
With evolving guidelines in many different treatment areas, the ACCP is moving toward living guidelines that keep pace with a rapidly changing evidence landscape, according to Daniel Oulette, MD, FCCP, leader of ACCP’s guideline oversight committee.
When developing any guideline, investigators look at 4 important questions:
Establishing the strength of evidence behind each recommendation is an important priority for the ACCP. However, more recently, guidelines are becoming “a mix between consensus statements and guidelines.” This is important, because not all clinical practices can be rigorously supported by evidence.
Consensus statements are arrived at through an iterative voting process known as the Delphi model. For a consensus statement to be included in any CHEST guideline, a level of 80% consensus is necessary, stated Dr Oulette. Guideline statements are also phrased in such a way that compliance with recommendations can be monitored. The ability to monitor is critical to implementing quality improvement programs.
Literature is monitored continuously by the ACCP, and future ACCP guidelines will not be published in journals, but will be available at websites and updated continuously. According to Dr Oulette, “There will be a Web page for each of the guidelines with links to supportive text and supportive evidence tables....These are living guidelines.”
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More